Vikramaditya Gangakar/LinkedIn
Apr 29, 2026, 16:41
Vikramaditya Gangakar: Essential Pharmacy Facts You Should Know About Aspirin
Vikramaditya Gangakar, Pharmacy Technician at Ain Al Khaleej Hospital, shared a post on LinkedIn:
“Aspirin: essential pharmacy facts you must know!
- Most used antiplatelet, but high bleeding risk
- Key pharmacology point
- Class: NSAID and Antiplatelet
- Mechanism:
- Irreversible COX-1 inhibition leads to decreased Thromboxane A₂ leads to decreased platelet aggregation
- Also increased prostaglandins lead to pain and fever relief
Indications
- Cardioprotection (low dose)
- Acute coronary syndrome (chewed dose)
- Pain relief
- Fever
- Inflammatory conditions
Forms and use
- Tablets (immediate / enteric-coated)
- Dispersible tablets
- Low-dose (75–150 mg) for antiplatelet use
Avoid/ caution
- Children with viral infections (Reye’s syndrome)
- Peptic ulcer / GI bleed history
- Elderly (high bleeding risk)
- NSAID-sensitive asthma
Dangerous combos
- Anticoagulants (e.g., warfarin): increases the risk of bleeding
- Other NSAIDs lead to increased GI toxicity
- Steroids lead to increased ulcer risk
Brand names (global and UAe)
- Ecosprin
- Disprin
- Bayer Aspirin
Pro tip:
- Use low dose for heart, high dose for pain (with caution)!
Mind-blowing fact
One tablet can affect platelets for 7–10 days!
Your practice?
Do you check bleeding risk before recommending aspirin?”
Stay updated with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian